Systematic review of microsatellite instability and colorectal cancer prognosis - PubMed (original) (raw)
Review
. 2005 Jan 20;23(3):609-18.
doi: 10.1200/JCO.2005.01.086.
Affiliations
- PMID: 15659508
- DOI: 10.1200/JCO.2005.01.086
Review
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al. J Clin Oncol. 2005.
Abstract
Purpose: A number of studies have investigated the relationship between microsatellite instability (MSI) and colorectal cancer (CRC) prognosis. Although many have reported a better survival with MSI, estimates of the hazard ratio (HR) among studies differ. To derive a more precise estimate of the prognostic significance of MSI, we have reviewed and pooled data from published studies.
Methods: Studies stratifying survival in CRC patients by MSI status were eligible for analysis. The principal outcome measure was the HR. Data from eligible studies were pooled using standard techniques.
Results: Thirty-two eligible studies reported survival in a total of 7,642 cases, including 1,277 with MSI. There was no evidence of publication bias. The combined HR estimate for overall survival associated with MSI was 0.65 (95% CI, 0.59 to 0.71; heterogeneity P = .16; I(2) = 20%). This benefit was maintained restricting analyses to clinical trial patients (HR = 0.69; 95% CI, 0.56 to 0.85) and patients with locally advanced CRC (HR = 0.67; 95% CI, 0.58 to 0.78). In patients treated with adjuvant fluorouracil (FU) CRCs with MSI had a better prognosis (HR = 0.72; 95% CI, 0.61 to 0.84). However, while data are limited, tumors with MSI derived no benefit from adjuvant FU (HR = 1.24; 95% CI, 0.72 to 2.14).
Conclusion: CRCs with MSI have a significantly better prognosis compared to those with intact mismatch repair. Additional studies are needed to further define the benefit of adjuvant chemotherapy in locally advanced tumors with MSI.
Similar articles
- Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I, Boulay JL, Heinimann K, Ballabeni P, Terracciano L, Laffer U, Mild G, Herrmann R, Rochlitz C. Storojeva I, et al. Oncol Rep. 2005 Jul;14(1):241-9. Oncol Rep. 2005. PMID: 15944796 - Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Hemminki A, et al. Gastroenterology. 2000 Oct;119(4):921-8. doi: 10.1053/gast.2000.18161. Gastroenterology. 2000. PMID: 11040179 - Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis.
Walther A, Houlston R, Tomlinson I. Walther A, et al. Gut. 2008 Jul;57(7):941-50. doi: 10.1136/gut.2007.135004. Epub 2008 Mar 25. Gut. 2008. PMID: 18364437 Review. - Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML, Hewett PJ, Ruszkiewicz AR, Moore JW. Thomas ML, et al. Asia Pac J Clin Oncol. 2015 Dec;11(4):343-51. doi: 10.1111/ajco.12411. Epub 2015 Oct 15. Asia Pac J Clin Oncol. 2015. PMID: 26471980 - Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer.
Aggarwal N, Quaglia A, McPhail MJW, Monahan KJ. Aggarwal N, et al. Int J Colorectal Dis. 2022 Jan;37(1):35-46. doi: 10.1007/s00384-021-04046-x. Epub 2021 Oct 22. Int J Colorectal Dis. 2022. PMID: 34677685 Free PMC article. Review.
Cited by
- Establishment and Validation of a Prognostic Nomogram for Predicting Postoperative Overall Survival in Advanced Stage III-IV Colorectal Cancer Patients.
Lou P, Luo D, Huang Y, Chen C, Yuan S, Wang K. Lou P, et al. Cancer Med. 2024 Nov;13(22):e70385. doi: 10.1002/cam4.70385. Cancer Med. 2024. PMID: 39546402 Free PMC article. - A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade.
Ibruli O, Rose F, Beleggia F, Schmitt A, Cartolano M, Fernandez LT, Saggau J, Bonasera D, Kiljan M, Gozum G, Lichius L, Cai J, Niu LN, Caiaffa MI, Herter JM, Walczak H, Liccardi G, Grüll H, Büttner R, Bosco G, George J, Thomas RK, Bozek K, Reinhardt HC, Herter-Sprie GS. Ibruli O, et al. J Cancer Res Clin Oncol. 2024 Nov 14;150(11):496. doi: 10.1007/s00432-024-05942-9. J Cancer Res Clin Oncol. 2024. PMID: 39542886 Free PMC article. - Development of oxidative stress- and ferroptosis-related prognostic signature in gastric cancer and identification of CDH19 as a novel biomarker.
Wang S, Zhang S, Li X, Leng C, Li X, Lv J, Zhao S, Qiu W, Guo J. Wang S, et al. Hum Genomics. 2024 Nov 5;18(1):121. doi: 10.1186/s40246-024-00682-w. Hum Genomics. 2024. PMID: 39501397 Free PMC article. - Genetics, diet, microbiota, and metabolome: partners in crime for colon carcinogenesis.
La Vecchia M, Sala G, Sculco M, Aspesi A, Dianzani I. La Vecchia M, et al. Clin Exp Med. 2024 Oct 29;24(1):248. doi: 10.1007/s10238-024-01505-x. Clin Exp Med. 2024. PMID: 39470880 Free PMC article. Review. - Revolutionizing prognostic predictions in colorectal cancer: Macrophage‑driven transcriptional insights from single‑cell RNA sequencing and gene co‑expression network analysis.
Feng Y, Cheng Z, Gao J, Huang T, Wang J, Tang Q, Pu K, Liu C. Feng Y, et al. Oncol Lett. 2024 Oct 3;28(6):587. doi: 10.3892/ol.2024.14721. eCollection 2024 Dec. Oncol Lett. 2024. PMID: 39411205 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical